A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Phase: Phase II-III clinical trials
Principal Investigator: Dott.ssa Verzoni Elena
Main Facility: Oncologia Medica Genitourinaria
Drug: Xaluritaming + Abiraterone versus Docetaxel, Cabazitaxel e Abiraterone
Pathologies: Prostate tumors
This is a randomized, multicenter, open-label, phase 3 study to compare the efficacy and safety of xaluritamig plus abiraterone against investigator’s choice of docetaxel, cabazitaxel, or abiraterone in participants with chemotherapy-naïve mCRPC.
Last update: 20/04/2026